2013
Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)?
Hafeez F, Neboori HJ, Harigopal M, Wu H, Haffty BG, Yang Q, Schiff D, Moran MS. Is Ki-67 Expression Prognostic for Local Relapse in Early-Stage Breast Cancer Patients Treated With Breast Conservation Therapy (BCT)? International Journal Of Radiation Oncology • Biology • Physics 2013, 87: 344-348. PMID: 23910708, DOI: 10.1016/j.ijrobp.2013.05.052.Peer-Reviewed Original ResearchConceptsBreast conservation therapyEarly-stage breast cancer patientsHuman epidermal growth factor receptor 2Recurrence-free survivalBreast cancer patientsKi-67 expressionKi-67Clinicopathologic featuresConservation therapyCancer patientsIndependent associationLocoregional recurrence-free survivalDistant metastasis-free survivalLocal relapse-free survivalEpidermal growth factor receptor 2Univariate/multivariate analysisPrognostic clinicopathologic featuresCause-specific survivalHormone receptor statusGrowth factor receptor 2Metastasis-free survivalRelapse-free survivalKi-67 overexpressionSignificant independent associationKi-67 staining
1998
Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy
Moran M, Haffty B. Lobular carcinoma in situ as a component of breast cancer: The long-term outcome in patients treated with breast-conservation therapy. International Journal Of Radiation Oncology • Biology • Physics 1998, 40: 353-358. PMID: 9457821, DOI: 10.1016/s0360-3016(97)00573-7.Peer-Reviewed Original ResearchConceptsPercentage of patientsBreast cancer patientsLong-term outcomesConservative surgeryControl groupRadiation therapyHistologic componentsPrimary histologyLobular carcinomaCancer patientsBreast cancerComparable local control ratesDistant disease-free survivalTumor recurrence-free survivalDisease-free survivalLocal control rateRecurrence-free survivalAge of presentationBreast conservation therapyEstrogen receptor statusSignificant differencesReexcision specimenResidual LCISAdjuvant therapyBilateral disease